Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
Want to see UNCY full AI Analyst Report?
Top Page
Unicycive Therapeutics
(NASDAQ:UNCY)
Select Model
Select Model
Rating:48Neutral
Price Target:
$7.00
▼(-0.28% Downside)
Action:ReiteratedDate:04/02/26
The score is held down primarily by weak financial performance (pre-revenue operations, sizable losses, and high cash burn), partially offset by a low-debt balance sheet and improved equity position. Technicals are modestly supportive with the stock trading above major moving averages, but valuation remains constrained by negative earnings and no dividend.
Positive Factors
Targeted CKD dialysis therapy (OLC)
OLC targets a clearly defined, chronic treatment need in dialysis patients with hyperphosphatemia. If approved, an oral phosphate binder addresses ongoing therapy demand and established distribution channels (dialysis providers, pharmacies, hospitals), supporting durable commercial opportunity.
Negative Factors
High cash burn
Persistently negative operating cash flow at this scale consumes capital rapidly and makes the company dependent on periodic fundraising. Over a multi-month horizon this raises dilution and execution risk if financing windows tighten, constraining development and commercialization timelines.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted CKD dialysis therapy (OLC)
OLC targets a clearly defined, chronic treatment need in dialysis patients with hyperphosphatemia. If approved, an oral phosphate binder addresses ongoing therapy demand and established distribution channels (dialysis providers, pharmacies, hospitals), supporting durable commercial opportunity.
Read all positive factors
Unicycive Therapeutics (UNCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$183.98M
Dividend YieldN/A
Average Volume (3M)473.55K
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS Growth80.61%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding25,237,782
10 Day Avg. Volume543,143
30 Day Avg. Volume473,551
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)30.36
Price to Sales (P/S)0.00
P/FCF Ratio-29.25
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-300.92
Enterprise Value/Ebitda-4.92
Forecast
1Y Price Target
$49.83Price Target Upside609.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$64.03M
Unicycive Therapeutics Business Overview & Revenue Model
Company Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 49...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Unicycive’s ability to generate recurring commercial revenue depends primarily on obtaining regulatory approval and commercializing its product candidates (notably OLC). If OLC is approved, the compan...
Unicycive Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 675.00K | 951.00K | 0.00 |
| Gross Profit | -572.00K | 0.00 | 675.00K | 951.00K | 0.00 |
| EBITDA | -25.91M | -36.23M | -30.18M | -17.89M | -9.38M |
| Net Income | -26.55M | -36.73M | -30.54M | -18.06M | -10.02M |
Balance Sheet | |||||
| Total Assets | 49.13M | 31.67M | 14.19M | 2.82M | 18.74M |
| Cash, Cash Equivalents and Short-Term Investments | 41.27M | 26.14M | 9.70M | 455.00K | 16.58M |
| Total Debt | 117.00K | 773.00K | 811.00K | 201.00K | 335.00K |
| Total Liabilities | 18.94M | 24.24M | 18.00M | 3.28M | 2.26M |
| Stockholders Equity | 30.20M | 7.43M | -3.81M | -466.00K | 16.48M |
Cash Flow | |||||
| Free Cash Flow | -31.34M | -28.65M | -18.30M | -15.65M | -5.80M |
| Operating Cash Flow | -31.32M | -28.57M | -18.28M | -15.65M | -5.77M |
| Investing Cash Flow | -12.10M | -72.00K | -12.00K | -2.00K | -29.00K |
| Financing Cash Flow | 46.47M | 45.09M | 27.54M | -471.00K | 22.38M |
Unicycive Therapeutics Technical Analysis
Positive
7.02
Price Trends
6.68
Positive
6.43
Positive
5.49
Positive
Market Momentum
0.06
Negative
56.09
Neutral
71.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Positive. The current price of 7.02 is above the 20-day moving average (MA) of 6.69, above the 50-day MA of 6.68, and above the 200-day MA of 5.49, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 56.09 is Neutral, neither overbought nor oversold. The STOCH value of 71.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UNCY.
Unicycive Therapeutics Risk Analysis
Unicycive Therapeutics disclosed 57 risk factors in its most recent earnings report. Unicycive Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Unicycive Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $136.57M | -6.36 | -119.19% | ― | -100.00% | -123.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $75.03M | -6.48 | 15.86% | ― | 9.69% | 98.38% | |
48 Neutral | $183.98M | -15.62 | -111.37% | ― | ― | 80.61% | |
45 Neutral | $114.26M | -6.26 | -236.85% | ― | -14.62% | 72.19% | |
43 Neutral | $27.07M | -1.93 | -226.10% | ― | ― | 63.57% |
* Healthcare Sector Average
UNCY
Unicycive Therapeutics
7.29
0.80
12.33%
CVM
Cel-Sci
3.20
-5.92
-64.90%
FBIO
Fortress Biotech
2.33
0.65
38.69%
CBUS
Cibus
1.50
-0.50
-25.00%
EQ
Equillium
2.16
1.70
371.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.